Results 31 to 40 of about 30,023 (219)

Recurrent pericarditis: a case report and literature review

open access: yesActa Medica Lituanica, 2017
Background. Recurrence affects about 30% (20% to 50%) of patients within 18 months after the initial episode of acute pericarditis resulting in subsequent rehospitalizations.
Justina Katinaitė   +1 more
doaj   +1 more source

Report of a case of purulent pericarditis in a post cholecystectomy patient

open access: yesUniversidad Médica Pinareña, 2021
Introduction: purulent pericarditis is defined as an inflammation of the pericardium associated with the occupation of the pericardial sac by purulent fluid.
Carlos Enrique Salgado-Fuentes   +2 more
doaj  

Electrocardiogram evolution of acute anterior ST‐segment elevation myocardial infarction following pericarditis

open access: yesAnnals of Noninvasive Electrocardiology, 2022
Electrocardiogram is a powerful tool for differentiating acute ST‐segment elevation myocardial infarction (STEMI) and pericarditis. However, an unusual ECG presentation of the simultaneous occurrence of the two conditions has not been reported previously.
Xiaopeng Bai   +5 more
doaj   +1 more source

Atrial Fibroblasts‐Derived Extracellular Vesicles Exacerbate Atrial Arrhythmogenesis

open access: yesAdvanced Science, EarlyView.
Exosome miR‐224‐5p derived from angiotensin II‐treated atrial fibroblasts creates a substrate for AF by promoting atrial electrical remodeling. Increased exosome miR‐224‐5p enhances AF susceptibility by inhibiting CACNA1c expression and decreasing ICa current of atrial cardiomyocytes.
Yue Yuan   +13 more
wiley   +1 more source

Autopsy findings in cases of fatal COVID‐19 vaccine‐induced myocarditis

open access: yesESC Heart Failure, EarlyView.
Abstract COVID‐19 vaccines have been linked to myocarditis, which, in some circumstances, can be fatal. This systematic review aims to investigate potential causal links between COVID‐19 vaccines and death from myocarditis using post‐mortem analysis.
Nicolas Hulscher   +3 more
wiley   +1 more source

Interleukin-1 Blockers in Recurrent and Acute Pericarditis: State of the Art and Future Directions. [PDF]

open access: yesMedicina (Kaunas)
Diseases of the pericardium encompass a spectrum of conditions, including acute and recurrent pericarditis, where inflammation plays a pivotal role in the pathogenesis and clinical manifestations. Anti-inflammatory therapy indeed forms the cornerstone of
Gallo A   +9 more
europepmc   +2 more sources

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli   +17 more
wiley   +1 more source

A Rare Case of Primary Purulent Pericarditis Caused by Streptococcus constellatus

open access: yesMedicina, 2023
Background: Bacteria-caused acute pericarditis is a very rare entity. It is usually associated with an underlying infection or compromised immune system. Primary purulent pericarditis in a previously healthy individual is highly unexpected; therefore, it
Medeinė Kapačinskaitė   +6 more
doaj   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher   +12 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Cardiovascular Adverse Events

open access: yesESC Heart Failure, EarlyView.
Abstract In the last years, we assisted to a tremendous increase in therapeutic options for the management of cancers, with immunotherapy at the forefront of this innovation. Immune checkpoint inhibitors (ICIs) have been developed to enhance the activity of the immune system against cancer cells (1) and the number of approvals for ICIs has rapidly ...
Maria Luisa De Perna   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy